Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Neuroblastoma 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoproliferative Disorders 1Lymphoma 1Lung Neoplasms 1Leukemia 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

dacetuzumab 4tetulomab tetraxetan lu-177 2Rituximab 2Lutetium 2Gemcitabine 2vandetanib 1tirbanibulin 1phenethyl isothiocyanate 1motesanib diphosphate 1imetelstat 1fludarabine 1ficlatuzumab 1denileukin diftitox 1beta-Glucans 1Nivolumab 1Lutetium-177 1Lenalidomide 1Immunoenzyme Techniques 1Ganciclovir 1Erlotinib Hydrochloride 1Dexamethasone 1Clofarabine 1Calcium Dobesilate 1Bortezomib 1Bevacizumab 1Bendamustine Hydrochloride 1AP 1903 reagent 14,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoproliferative Disorders × beta-Glucans × Clear all
NCT00087009 2013-03-19

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

Memorial Sloan Kettering Cancer Center

Phase 1 Terminated
3 enrolled
LymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoproliferative Disorders, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡